Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety and immunogenicity of Fc-EDA, a recombinant ectodysplasin A1 replacement protein, in human subjects.

British journal of clinical pharmacology·2020

Same author

Natural history of X-linked hypohidrotic ectodermal dysplasia: a 5-year follow-up study.

Orphanet journal of rare diseases·2020

Same author

Prenatal Treatment of X-Linked Hypohidrotic Ectodermal Dysplasia using Recombinant Ectodysplasin in a Canine Model.

The Journal of pharmacology and experimental therapeutics·2019

Same author

A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma.

American journal of ophthalmology·2018

Same author

Automatic recognition of the XLHED phenotype from facial images.

American journal of medical genetics. Part A·2017

Same author

Pharmacological activation of the EDA/EDAR signaling pathway restores salivary gland function following radiation-induced damage.

PloS one·2014

Search research articles

Related Experiment Video

Updated: May 1, 2026

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia

Published on: January 6, 2018

Future developments in XLHED treatment approaches.

Kenneth Huttner¹

¹Clinical Development, Edimer Pharmaceuticals, Cambridge, Massachusetts.

American Journal of Medical Genetics. Part A

|March 29, 2014

Summary

This summary is machine-generated.

X-linked hypohidrotic ectodermal dysplasia (XLHED) is a genetic disorder affecting ectoderm development. A novel protein replacement therapy (EDI200) shows promise for permanent correction in animal models, with human trials imminent.

Keywords:

animal models ectodermal dysplasia protein therapeutic

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Related Experiment Videos

Last Updated: May 1, 2026

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia

Published on: January 6, 2018

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Area of Science:

Genetics
Developmental Biology
Regenerative Medicine

Background:

X-linked hypohidrotic ectodermal dysplasia (XLHED) is a prevalent genetic disorder impacting ectodermal development, leading to significant abnormalities in skin, teeth, hair, and glands.
XLHED poses life-threatening risks in infancy, including hyperthermia and pulmonary infections, and results in chronic health issues throughout life.
Current therapeutic options for XLHED are limited, with no approved treatments to restore lost function in this developmental disorder.

Purpose of the Study:

To investigate the potential of ectodysplasin (EDA) gene replacement therapy for XLHED.
To evaluate the efficacy of EDA-A1 replacement protein (EDI200) in correcting XLHED phenotypes.
To translate findings from animal models to a potential human therapy for XLHED.

Main Methods:

Utilized established mouse and dog models of XLHED.
Administered a single course of EDA-A1 replacement protein (EDI200) to XLHED animal models.
Assessed the long-term phenotypic correction of key XLHED features in treated animals.

Main Results:

A single course of EDI200 resulted in the permanent correction of major phenotypic features in XLHED mouse and dog models.
EDI200 demonstrated the potential for effective, targeted therapy in XLHED.
Animal model studies provide a strong foundation for human clinical trials.

Conclusions:

The study provides the first evidence for a targeted therapy (EDI200) with potential for permanent correction of XLHED.
Translating these findings into human trials represents a novel paradigm for treating human developmental disorders.
FDA clearance for EDI200 studies in XLHED patients marks a significant step towards clinical application.